Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer

Clinical Cancer Research

Volumn 16, Issue 19, 2010, Pages 4899-4905

  Ledermann, Jonathan A ^a,c   Gabra, Hani ^b   Jayson, Gordon C ^d   Spanswick, Victoria J ^c   Rustin, Gordon J S ^e   Jitlal, Mark ^c   James, Lindsay E ^c   Hartley, John A ^c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; PLATINUM DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMET ASSAY; COMPETITIVE INHIBITION; DNA CROSS LINKING; DNA REPAIR; DRUG DOSE REDUCTION; DRUG POTENTIATION; EX VIVO STUDY; FEBRILE NEUTROPENIA; FEMALE; GEL ELECTROPHORESIS; HUMAN; NAUSEA; OPEN STUDY; OVARY CANCER; OVARY CARCINOMA; PERIPHERAL LYMPHOCYTE; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957564535     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0832     Document Type: Article

References (27)

1. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59:650-3. (Pubitemid 19111764)
2. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
3. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3. (Pubitemid 24330217)
4. BergmanAM, Ruiz van HaperenVW, Veerman G, KuiperCM, PetersGJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-30. (Pubitemid 26099172)
5. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88:35-9. (Pubitemid 36067331)
6. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003;88:17-21. (Pubitemid 36062660)
7. Fichtinger-Schepman AM, van Dijk-Knijnenburg HC, van der Velde-Visser SD, Berends F, Baan RA. Cisplatin- and carboplatin- DNA adducts: is PT-AG the cytotoxic lesion? Carcinogenesis 1995; 16:2447-53.
8. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
9. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA, Hartley JA. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007;97:927-33. (Pubitemid 47519316)
10. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003;63:862-9.
11. Rustin GJ, Quinn M, Thigpen T, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96:487-8.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
13. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-12.
14. Spanswick V, Hartley J, Ward T, Hartley J. Measurement of drug-induced DNA interstrand crosslinking using the single cell gel electrophoresis (comet) assay. In: Brown R, Boger-Brown U, editors. Methods in molecular medicine. New York: Humana Press; 1999, p. 143-54.
15. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 1990;122:86-94.
16. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88:266-9.
17. Bozas G, Bamias A, Koutsoukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 2007;104:580-5.
18. Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;103:446-50.
19. Tewari D, Monk BJ, Hunter M, Falkner CA, Burger RA. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 2004;22:475-80.
20. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22:72-9.
21. van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-smallcell lung cancer cell lines. Br J Cancer 1999;80:981-90.
22. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6 Suppl 6:7-13.
23. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-25.
24. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, the EORTC GCG. J Clin Oncol 2006;24:4699-707.
25. Havrilesky LJ, Alvarez AA, Sayer RA, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003;88:51-7.
26. KatsumataN,YasudaM, Takahashi F, et al.Dose-dense paclitaxel once a week in combinationwith carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374:1331-8.
27. Alvarez RD, Mannel R, Garcia AA, et al. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm phase I study. Gynecol Oncol 2009;115:389-95.